Quantification of disease progression and dropout for Alzheimer's disease

International Journal of Clinical Pharmacology and Therapeutics

Volumn 51, Issue 2, 2013, Pages 120-131

  William Faltaos, Demiana ^a   Chen, Ying ^a   Wang, Yaning ^a   Gobburu, Jogarao ^a   Zhu, Hao ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Alzheimer's disease model; Disease model; Dropout model

Indexed keywords

PLACEBO;

ACCURACY; ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CALCULATION; CLINICAL STUDY; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; FEMALE; HUMAN; INTERMETHOD COMPARISON; LOGLINEAR MODEL; MAJOR CLINICAL STUDY; MALE; PREDICTION; RATING SCALE; SCORING SYSTEM; SIMULATION; STATISTICAL MODEL; TREATMENT DURATION; TREATMENT WITHDRAWAL;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; COGNITION; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MODELS, STATISTICAL; NEUROPSYCHOLOGICAL TESTS; PATIENT DROPOUTS; PLACEBOS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84873867379     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CP201787     Document Type: Article

References (22)

1. Mayeux R, Sano M. Treatment of Alzheimer's disease. N Engl J Med. 1999; 341: 1670-1679. doi:10.1056/NEJM199911253412207 PubMed
2. Rafii MS, Aisen PS. Recent developments in Alzheimer's disease therapeutics. BMC Med. 2009; 7: 7. doi:10.1186/1741-7015-7-7 PubMed
3. Becker RE, Greig NH. Alzheimer's disease drug development in 2008 and beyond: problems and opportunities. Curr Alzheimer Res. 2008; 5: 346-357. doi:10.2174/156720508785132299 PubMed
4. Pleckaityte M. [Alzheimer's disease: a molecular mechanism, new hypotheses, and therapeutic strategies]. Medicina (Kaunas). 2010; 46: 70-76. PubMed
5. Holford NH, Peace KE. Results and validation of a population pharmacodynamic model for cognitive effects in Alzheimer patients treated with tacrine. Proc Natl Acad Sci USA. 1992; 89: 11471-11475. doi:10.1073/pnas.89.23. 11471 PubMed
6. Burns A. Alzheimer's disease: on the verges of treatment and prevention. Lancet Neurol. 2009; 8: 4-5. doi:10.1016/S1474-4422(08)70271-0 PubMed
7. Ellis JM, Kuti JL, Nicolau DP. Use of Monte Carlo simulation to assess the pharmacodynamics of beta-lactams against Pseudomonas aeruginosa infections in children: a report from the OPTAMA program. Clin Ther. 2005; 27: 1820-1830. doi:10.1016/j.clinthera.2005.11.007 PubMed
8. Stern RG, Mohs RC, Davidson M, Schmeidler J, Silverman J, Kramer-Ginsberg E, Searcey T, Bierer L, Davis KL. A longitudinal study of Alzheimer's disease: measurement, rate, and predictors of cognitive deterioration. Am J Psychiatry. 1994; 151: 390-396. PubMed
9. Doraiswamy PM, Bieber F, Kaiser L, Krishnan KR, Reuning-Scherer J, Gulanski B. The Alzheimer's Disease Assessment Scale: patterns and predictors of baseline cognitive performance in multicenter Alzheimer's disease trials. Neurology. 1997; 48: 1511-1517. doi:10.1212/WNL.48.6.1511 PubMed
10. Holford NH, Peace KE. Methodologic aspects of a population pharmacodynamic model for cognitive effects in Alzheimer patients treated with tacrine. Proc Natl Acad Sci USA. 1992; 89: 11466-11470. doi:10.1073/pnas.89.23. 11466 PubMed
11. Holford NH, Peace K. The effect of tacrine and lecithin in Alzheimer's disease. A population pharmacodynamic analysis of five clinical trials. Eur J Clin Pharmacol. 1994; 47: 17-23. PubMed
12. Ito K, Ahadieh S, Corrigan B, French J, Fullerton T, Tensfeldt T; Alzheimer's Disease Working Group. Disease progression meta-analysis model in Alzheimer's disease. Alzheimers Dement. 2010; 6: 39-53. doi:10.1016/j.jalz.2009. 05.665 PubMed
13. Samtani MN, Farmum M, Lobanov V, Yang E, Raghavan N, Dibermardo A, Narayan V, Initiative AD. An Improved Model for Disease Progression in Patients From the Alzheimer's Disease Neuroimaging Initiative. J Clin Pharmacol. 2011; 9: 1-16. PubMed
14. van Marum RJ. Current and future therapy in Alzheimer's disease. Fundam Clin Pharmacol. 2008; 22: 265-274. doi:10.1111/j.1472-8206.2008.00578.x PubMed
15. Frisoni GB, Delacourte A. Neuroimaging outcomes in clinical trials in Alzheimer's disease. J Nutr Health Aging. 2009; 13: 209-212. doi:10.1007/s12603-009-0060-7 PubMed
16. Blennow K, Zetterberg H. Use of CSF biomarkers in Alzheimer's disease clinical trials. J Nutr Health Aging. 2009; 13: 358-361. doi:10.1007/s12603-009- 0043-8 PubMed
17. Schneider LS, Sano M. Current Alzheimer's disease clinical trials: methods and placebo outcomes. Alzheimers Dement. 2009; 5: 388-397. doi:10.1016/j.jalz.2009.07.038 PubMed
18. Ploeger BA, Holford NH. Washout and delayed start designs for identifying disease modifying effects in slowly progressive diseases using disease progression analysis. Pharm Stat. 2009; 8: 225-238. doi:10.1002/pst.355 PubMed
19. Ito K, Corrigan B, Zhao Q, French J, Miller R, Soares H, Katz E, Nicholas T, Billing B, Anziano R, Fullerton T; Alzheimer's Disease Neuroimaging Initiative. Disease progression model for cognitive deterioration from Alzheimer's Disease Neuroimaging Initiative database. Alzheimers Dement. 2011; 7: 151-160. doi:10.1016/j. jalz.2010.03.018 PubMed
20. Antuono PG, Antuono PG, Ravanelli-Meyer J, Beyer J, Brown WA, Cordoza J, Guilmette D, Cohen SR, Hirsch CJ, Cohen KG, DeLaGandara JE, Pedraza A, Bley S, Dean DL, Manor S, Holub RF, Holub SB, Siciliano N, Little JH, Crismon ML, et al; Mentane Study Group. Effectiveness and safety of velnacrine for the treatment of Alzheimer's disease. A double-blind, placebo-controlled study. Arch Intern Med. 1995; 155: 1766-1772. doi:10.1001/archinte.1995.00430160102010 PubMed
21. Feldman HH, Van Baelen B, Kavanagh SM, Torfs KE. Cognition, function, and caregiving time patterns in patients with mild-to-moderate Alzheimer disease: a 12-month analysis. Alzheimer Dis Assoc Disord. 2005; 19: 29-36. doi:10.1097/01. wad.0000157065.43282.bc PubMed
22. Kaduszkiewicz H. An innovative approach to involve patients in measuring treatment effects in drug trials. CMAJ. 2006; 174: 1117-1118. doi:10.1503/cmaj.060261 PubMed